Selecting antiepileptic drugs for symptomatic patients with brain tumors

Journal of Supportive Oncology

Volumn 4, Issue 8, 2006, Pages 411-416

  Thompson, Diane ^a,b,e   Takeshita, Junji ^b   Thompson, Todd ^d   Mulligan, Meagan ^c  

^a Cancer Center Program   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d Hawaii Neurosurgery Group   (United States)

^e Hawaii Neurosurgery Group ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LAMOTRIGINE; PANTOPRAZOLE; PHENYTOIN; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CRYING; CYTOREDUCTIVE SURGERY; DEPRESSION; DRUG SUBSTITUTION; FRUSTRATION; GLIOBLASTOMA; HELPLESSNESS; HUMAN; LETHARGY; MALE; PATIENT REFERRAL; SEIZURE; SELF ESTEEM; WEIGHT GAIN;

AFFECT; ANTICONVULSANTS; ANXIETY; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PAIN; PALLIATIVE CARE; SEIZURES;

EID: 33749627723     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996;46:985-991.
2. Oberndorfer S, Schmal T, Lahrmann H, et al. The frequency of seizures in patients with primary brain tumors or cerebral metastases: an evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna [in German]. Wien Klin Wochenschr 2002;114:911-916.
3. Temkin NR. Prophylactic anticonvulsants after neurosurgery. Epilepsy Curr 2002;2:105-107.
4. Suri A, Mahapatra AK, Bithal P. Seizures following posterior fossa surgery. Br J Neurosurg 1998;12:41-44.
5. Hwang SL, Lin CL, Lee KS, et at. Factors influencing seizures in adult patients with supratentorial astrocytic tumors. Acta Neurochir (Wien) 2004;146:589-594.
6. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000;54:1886-1893.
7. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 2002;57:41-49.
8. Madhusoodanan S, Abhishek S, Despina M. Brain tumors and psychiatric manifestations: a review and analysis. Poster presented at Annual Meeting of the American Association for Geriatric Psychiatry. March 10-13, 2006. San Juan, Puerto Rico.
9. Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J. Predicting major depression in brain tumor patients. Psychooncology 2002;11:230-238.
10. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003;54:283-294.
11. Rogers MP, Mendoza AY. Development of obsessive-compulsive disorder after brain tumor surgery and radiation. Psychosomatics 1994;35:402-406.
12. Capwell RR, Carter R. Organic anxiety syndrome secondary to metastatic brain tumor. Psychosomatics 1991;32:231-233.
13. Taillibert S, Laigle-Donadey F, Sanson M. Palliative care in patients with primary brain tumors. Curr Opin Oncol 2004;16:587-592.
14. Williams LS. Outcomes of newly referred neurology outpatients with depression and pain. Neurology 2004;63:674-677.
15. Mystakidou K, Rosenfeld B, Parpa E, et al. Desire for death near the end of life: the role of depression, anxiety and pain. Gen Hosp Psychiatry 2005;27:256-257.
16. Brooks JO 3rd, Hoblyn JC. Secondary mania in older adults. Am J Psychiatry 2005;162:2033-2038.
17. Mazure CM, Leibowitz K, Bowers MB Jr. Drug-responsive mania in a man with a brain tumor. J Neuropsychiatry Clin Neurosci 1999;11:114-115.
18. Gajwani P, Forsthoff A, Muzina D. Antiepileptic drugs in mood-disordered patients. Epilepsia 2005;46(suppl 4):38-44.
19. Mattes JA. Oxcarbazepine inpatients with impulsive aggression:a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005;25:575-579.
20. Gao K, Calabrese JR. Newer treatment studies for bipolar depression. Bipolar Disord 2005;7(suppl 5):13-23.
21. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Spotlight on lamotrigine in bipolar disorder. CNS Drugs 2004;18:63-67.
22. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today (Barc) 2005;41:547-555.
23. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002;4:207-213.
24. Carpenter LL, Schecter JM, Tyrka AR, et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 2006;67:66-71.
25. Bersudsky Y. Phenytoin: an anti-bipolar anticonvulsant? Int J Neuropsychopharmacol 2006;9:479-484.
26. Menigaux C, Adam F, Guignard B, Sessler DI, Chauvin M. Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg 2005;100:1394-1399.
27. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-1030.
28. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003;64:1245-1249.
29. Van Ameringen M, Mancini C, Patterson B, Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006;23:1-5.
30. Strolin Benedetti M, Ruty B, Baltes E. Induction of endogenous pathways by antiepileptics and clinical implications. Fundam Clin Pharmacol 2005;19:511-529.
31. Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2006;67:211-214.
32. Simon NM, Worthington JJ, Doyle AC, et al. An open label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004;65:1219-1222.
33. Rogawski MA. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res 2006;68:22-28.
34. Block F, Habermeyer B. Glutamate antagonists for treatment of neuropathic pain. Schmerz 2003;17:261-267.
35. Blackburn-Munro G, Erichsen HK. Antiepileptics and the treatment of neuropathic pain: evidence from animal models. Curr Pharm Des 2005;11:2961-2976.
36. Guay DR. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am J Geriatr Pharmacother 2005;3:274-287.
37. Rogawski LW. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004;10:685-693.
38. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28:277-279.
39. Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache:a randomized, placebo-controlled study. Neurology 2003;61:1753-1759.
40. Todorov AA, Koichev CB, Todorov AB. Tiagabine and gabapentin for the management of chronic pain. Clin J Pain 2005;21:358-361.
41. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 2004;20:33-36.
42. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(suppl 2):S53-S67.
43. Ketter TA, Malow BA, Flamini R, et al. Anticonvulsant withdrawal-emergent psychopathology. Neurology 1994;44:55-61.